Merus N.v.

Ono Pharmaceutical Co., Ltd.

Lava Therapeutics N.v.

Robertus Cornelis Roovers

Mark Throsby

Ton Logtenberg

Shiro Shibayama

Cornelis Adriaan De Kruif

Cecilia Anna Wilhelmina Geuijen

Pieter Fokko Van Loo

Rinse Klooster

Johannes Jelle Van Der Vliet

Tomoya Tezuka

Paul Willem Henri Ida Parren

Peter Alexander Gerardus Maria Machielsen

Victoria Iglesias Guimarais

Lisa Anna King

David Lutje Hulsik

The present invention relates to antibodies capable of binding human PSMA and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

Antibodies that bind PSMA and gamma-delta T cell receptors

An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.

Bispecific antibody

The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.

Methods of treating a subject having an EGFR-positive and/or ErbB-3-positive tumor

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

Antibodies that bind EGFR and cMET

Antibodies that bind EGFR and ErbB3

Growing community of inventors

Utrecht, Netherlands

Robertus Cornelis Roovers